MX2017013453A - Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica. - Google Patents
Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica.Info
- Publication number
- MX2017013453A MX2017013453A MX2017013453A MX2017013453A MX2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A
- Authority
- MX
- Mexico
- Prior art keywords
- dioxido
- thiazine
- methanone
- benzo
- hydroxy
- Prior art date
Links
- OJLQZOLPGURZRX-UHFFFAOYSA-N C1=CC=C2S(=O)(=O)N(C)C(C(=O)C=3C=C4C=CC=CC4=CC=3)=C(O)C2=C1 Chemical compound C1=CC=C2S(=O)(=O)N(C)C(C(=O)C=3C=C4C=CC=CC4=CC=3)=C(O)C2=C1 OJLQZOLPGURZRX-UHFFFAOYSA-N 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1553574A FR3035326B1 (fr) | 2015-04-21 | 2015-04-21 | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| PCT/EP2016/058760 WO2016169983A1 (fr) | 2015-04-21 | 2016-04-20 | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013453A true MX2017013453A (es) | 2017-12-07 |
Family
ID=53484018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013453A MX2017013453A (es) | 2015-04-21 | 2016-04-20 | Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180140609A1 (OSRAM) |
| EP (1) | EP3285774B1 (OSRAM) |
| JP (1) | JP2018513175A (OSRAM) |
| KR (1) | KR20170139030A (OSRAM) |
| CN (1) | CN107530355A (OSRAM) |
| AU (1) | AU2016251601A1 (OSRAM) |
| BR (1) | BR112017021586A2 (OSRAM) |
| CA (1) | CA2981933A1 (OSRAM) |
| FR (1) | FR3035326B1 (OSRAM) |
| MX (1) | MX2017013453A (OSRAM) |
| RU (1) | RU2017137262A (OSRAM) |
| WO (1) | WO2016169983A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102177304B1 (ko) | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| RU2706026C1 (ru) * | 2018-12-28 | 2019-11-13 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы | Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| JP2007197369A (ja) * | 2006-01-26 | 2007-08-09 | Sankyo Co Ltd | ベンゾチアジン誘導体 |
| FR2942797B1 (fr) * | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| KR101134447B1 (ko) * | 2009-11-30 | 2012-04-10 | 에스케이 주식회사 | 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 |
| JP2011213685A (ja) * | 2010-04-01 | 2011-10-27 | Kowa Co | ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤 |
| EP2563780B1 (en) * | 2010-04-29 | 2015-05-06 | The University Of Edinburgh | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1 |
| JP5901025B2 (ja) * | 2011-04-19 | 2016-04-06 | 第一三共株式会社 | テトラヒドロチアゼピン誘導体 |
-
2015
- 2015-04-21 FR FR1553574A patent/FR3035326B1/fr not_active Expired - Fee Related
-
2016
- 2016-04-20 BR BR112017021586-1A patent/BR112017021586A2/pt not_active Application Discontinuation
- 2016-04-20 MX MX2017013453A patent/MX2017013453A/es unknown
- 2016-04-20 EP EP16717911.8A patent/EP3285774B1/fr active Active
- 2016-04-20 AU AU2016251601A patent/AU2016251601A1/en not_active Abandoned
- 2016-04-20 RU RU2017137262A patent/RU2017137262A/ru not_active Application Discontinuation
- 2016-04-20 CA CA2981933A patent/CA2981933A1/fr not_active Abandoned
- 2016-04-20 WO PCT/EP2016/058760 patent/WO2016169983A1/fr not_active Ceased
- 2016-04-20 JP JP2017555239A patent/JP2018513175A/ja active Pending
- 2016-04-20 CN CN201680023190.6A patent/CN107530355A/zh active Pending
- 2016-04-20 US US15/568,085 patent/US20180140609A1/en not_active Abandoned
- 2016-04-20 KR KR1020177030299A patent/KR20170139030A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016169983A1 (fr) | 2016-10-27 |
| RU2017137262A3 (OSRAM) | 2019-09-30 |
| CN107530355A (zh) | 2018-01-02 |
| JP2018513175A (ja) | 2018-05-24 |
| EP3285774B1 (fr) | 2020-01-08 |
| BR112017021586A2 (pt) | 2018-07-03 |
| US20180140609A1 (en) | 2018-05-24 |
| FR3035326A1 (fr) | 2016-10-28 |
| FR3035326B1 (fr) | 2017-05-12 |
| EP3285774A1 (fr) | 2018-02-28 |
| RU2017137262A (ru) | 2019-05-21 |
| CA2981933A1 (fr) | 2016-10-27 |
| AU2016251601A1 (en) | 2017-11-30 |
| KR20170139030A (ko) | 2017-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY193818A (en) | Triazole agonists of the apj receptor | |
| MY199131A (en) | Human plasma kallikrein inhibitors | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| PH12015500724A1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
| MX370792B (es) | Composiciones para usarse en el tratamiento de cáncer. | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
| WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
| MX2015000618A (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. | |
| MY202127A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2017012535A (es) | Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| EP3518918A4 (en) | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | |
| MX2017014080A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| IL271236A (en) | Licofligozin for the treatment of non-alcoholic steatohepatitis | |
| NZ733451A (en) | Combination therapy for pulmonary hypertension | |
| MX373177B (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| EP3716975A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | |
| MX2017013453A (es) | Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica. | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| HK40017104A (en) | Licofligozin for the treatment of non-alcoholic steatohepatitis | |
| HK40012852A (en) | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis |